Gut bacteria, bile acids and inulin in people with irritable bowel syndrome
Studies gut bacteria and stool chemicals after inulin in irritable bowel syndrome patients and volunteers.
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
- Status
- Recruiting
- People taking part
- 72 people, planned
- Started
- 28 Nov 2024
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 3 groups
- Treatments tested
- Inulin
- Record updated
- 12 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with irritable bowel syndrome (IBS), with diarrhea (IBS-D) or constipation (IBS-C). It is also looking for healthy volunteers with no gut disease or symptoms. All follow a 4-day diet and take inulin.
- Age
- 18 to 75 years (the study groups describe 18-65 years)
- Sex
- All sexes can join
- Disease stage
- IBS with diarrhea (IBS-D) or with constipation (IBS-C), meeting Rome IV criteria. Healthy volunteers must have no past gut disease or symptoms.
- Earlier treatment
- No medicines that affect the gut (such as opioids, anti-inflammatory drugs or some antidepressants) within 6 months for healthy volunteers, or within 2 days for people with IBS. Stable low-dose antidepressants taken for more than one month are allowed. No antibiotics within 3 months. No prebiotics or probiotics within 2 weeks.
Main reasons for not taking part
- Inflammatory bowel disease, celiac disease, some abdominal cancers, thyroid or liver problems
- Belly surgery or radiation within 6 months (C-section or gallbladder removal allowed)
- Use of Ozempic or similar medicines
- Pregnant or breastfeeding women
- Regular tobacco use in the past 6 months, or a diet restriction other than vegetarian
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age 18-75
- Individuals with irritable bowel syndrome (IBS)
- Healthy volunteers (healthy controls) with no prior history of gastrointestinal (GI) disease or symptoms
- No dietary restrictions other than vegetarian
Who cannot take part
- Abdominal surgery or abdominal radiation within 6 months of study participation, with an exception for C-section or gallbladder removal
- Use of any prescription, over the counter, or herbal medications known to affect gastrointestinal function or study interpretation, such as opioids, inflammatory drugs or certain antidepressants, within 6 months prior to study participation for healthy volunteers, or within 2 days of study participation for participants with IBS
- Rescue medication such as Bisacodyl (dulcolax) to relieve severe constipation and allow for stool collection will be permitted when needed
- Use of Ozempic and Ozempic-type medications
- Use of prebiotics or probiotics within the 2 weeks before the study initiation
- Inflammatory bowel disease, celiac disease, or certain types of abdominal cancer, as well as those with thyroid or liver issues
- An exception will be permitted for limited use of stable low doses of antidepressants for individuals who have been taking them for a period greater than one month
- Pregnant or breastfeeding women
- Antibiotic use within 3 months of study participation
- Regular tobacco use within the past 6 months
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University of California, Los AngelesLos Angeles, United StatesContact: Ren CutrerTaking people
About the trial
What the trial wants to find out
The study will investigate the relationship between fecal bile acids, short-chain fatty acids (SCFAs), and the gut microbiota in irritable bowel syndrome (IBS). The central hypothesis of this study is that specific shifts in the GI microbiome composition correlate with altered colonic SCFAs and BAs and contribute to IBS symptoms. Primary aims include: (a) identifying GI microbiome signatures in IBS subtypes (IBS-C and IBS-D) and matched controls, and test if microbiome signatures in these groups correlate with fecal SCFAs and bacterial fermentation of an indigestible carbohydrate (inulin) after a dietary challenge (fecal inulin), and (b) determining if GI microbiome signatures in IBS subtypes and controls correlate with fecal BAs or markers of SCFA production (fecal SCFAs or inulin) and test if BAs correlate with fecal SCFAs or inulin.
Read full original descriptionShow less
The target population is adults ages 18-65 years meeting Rome IV criteria for IBS (both diarrhea- and constipation-predominant, IBS-D and IBS-C) and asymptomatic controls. Primary outcomes will be fecal bile acid excretion and profile, short-chain fatty acid excretion and profile, colonic transit, and fecal microbiota. Secondary outcomes will be stool characteristics based on responses to validated bowel diaries. Stool samples will be collected from participants during the last 2 days of a 4-day 100 g fat diet and split into 3 samples for fecal microbiota, SCFA, and bile acid analysis.
The 3 groups in the trial
- Healthy volunteersTreatment being tested
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Treatment: Inulin
- Irritable Bowel Syndrome Patients with Diarrhea (IBS-D)Treatment being tested
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS.
Treatment: Inulin
- Irritable Bowel Syndrome Patients with Constipation (IBS-C)Treatment being tested
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS.
Treatment: Inulin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Fecal Bile Acids, Fecal Short Chain Fatty Acids and the Intestinal Microbiota in Patients With Irritable Bowel Syndrome (IBS) and Control Volunteers: Diet Challenge
- Plain-language title
- Gut bacteria, bile acids and inulin in people with irritable bowel syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06668922, who can take part
- Record updated
- 12 August 2026